Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Representative image: A noninvasive colorectal cancer screening kit in a clinical setting, reflecting how Medicare coverage for Geneoscopy’s ColoSense could expand access to stool RNA-based colorectal cancer testing.
Medical Devices & Diagnostics

Geneoscopy’s ColoSense Medicare win puts stool RNA testing into the colorectal screening mainstream

Medicare coverage gives ColoSense a bigger test: can stool RNA screening move from FDA approval to real colorectal cancer adoption?

Read More
Representative image of biopharma laboratory research. Gilead Sciences and Merck’s latest Phase 3 updates highlight the promise of once-weekly HIV treatment with islatravir and lenacapavir, while raising fresh questions over Trodelvy’s lung cancer expansion strategy.
Pharma & Biotech

Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology

Gilead and Merck gain HIV momentum but face fresh oncology questions. See why this split pipeline update matters.

Read More
Representative image of cervical cancer treatment planning as Zai Lab’s TIVDAK approval expands China’s options for recurrent or metastatic disease.
Pharma & Biotech

TIVDAK approval gives Zai Lab a sharper China oncology story, but execution risk remains

TIVDAK enters China’s cervical cancer market with survival data. See why Zai Lab’s ADC approval matters beyond oncology headlines.

Read More
Pharma & Biotech

Why FDA approval for Hepcludex changes the treatment landscape for hepatitis delta virus

Find out how FDA approval for Gilead Sciences’ Hepcludex could reshape chronic hepatitis delta virus treatment in the U.S.

Read More
Representative image: A surgical team prepares a preserved donor heart in a high-tech transplant setting, reflecting the clinical and regulatory stakes behind United Therapeutics Corporation’s FDA-cleared UHeart xenotransplantation trial for end-stage heart failure.
Pharma & Biotech

Why United Therapeutics’ FDA-cleared UHeart trial could redefine xenotransplantation risk

Find out how United Therapeutics’ FDA-cleared UHeart trial could reshape xenotransplantation for end-stage heart failure patients.

Read More
Representative image of a robotic-assisted surgery system in a modern operating room, illustrating how Medtronic’s Hugo expansion filings could intensify competition in U.S. surgical robotics.
Medical Devices & Diagnostics

Medtronic pushes Hugo toward broader U.S. adoption as robotic surgery competition intensifies

Medtronic’s Hugo filings could widen U.S. robotic surgery competition. Find out how the FDA review may challenge Intuitive Surgical.

Read More
Representative image of a neurology consultation for normal pressure hydrocephalus, illustrating how CereVasc’s eShunt System could advance minimally invasive treatment beyond traditional shunt surgery.
Medical Devices & Diagnostics

Can CereVasc’s $85m raise move hydrocephalus treatment beyond traditional shunt surgery?

CereVasc’s $85m raise backs eShunt, a minimally invasive hydrocephalus device. The STRIDE trial now carries the real test.

Read More
Representative image of a patient using a portable ECG device during a remote cardiac consultation, illustrating how HeartBeam’s technology could move heart attack risk assessment closer to the patient.
Medical Devices & Diagnostics

HeartBeam’s peer-reviewed ECG data raises the stakes in remote cardiac diagnostics

HeartBeam’s ECG evidence could push chest pain assessment closer to patients. The next test is FDA clarity and clinical trust.

Read More
Representative image of clinicians reviewing AI-enabled radiation therapy planning scans, illustrating how GE HealthCare’s MIM Contour ProtégéAI+ 2.0 FDA clearance could speed precision cancer treatment workflows.
Medical Devices & Diagnostics

GE HealthCare’s MIM Contour ProtégéAI+ clearance raises the stakes in radiotherapy automation

GE HealthCare’s MIM Contour ProtégéAI+ 2.0 clearance could speed radiation therapy planning. Find out what changes next.

Read More
Representative image of an AI-enabled precision oncology research meeting, illustrating how SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center could turn cancer data into a precision medicine engine.
Medical Devices & Diagnostics

Can SOPHiA GENETICS and Memorial Sloan Kettering turn oncology data into a precision medicine engine?

SOPHiA GENETICS and Memorial Sloan Kettering aim to turn cancer data into precision oncology infrastructure. Can the hub deliver?

Read More